Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 36 articles:
HTML format
Text format



Single Articles


    December 2017
  1. SONG MA, Benowitz NL, Berman M, Brasky TM, et al
    Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    September 2017
  2. DENIS F, Lethrosne C, Pourel N, Molinier O, et al
    Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  3. CHAIB I, Karachaliou N, Pilotto S, Codony Servat J, et al
    Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    July 2017
  4. ROBLES AI, Harris CC
    Lung Cancer Field Cancerization: Implications for Screening by Low-Dose Computed Tomography.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    



  5. Shared Gene Expression Alterations in Nasal and Bronchial Epithelium for Lung Cancer Detection.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    June 2017
  6. KAWAKAMI M, Mustachio LM, Rodriguez-Canales J, Mino B, et al
    Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  7. LEE CK, Davies L, Wu YL, Mitsudomi T, et al
    Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    March 2017
  8. XU W, Neckers L
    A USE1ful Biomarker and Molecular Target in Lung Cancer?
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format    


  9. XU W, Neckers L
    Editorial: A USE1ful Biomarker and Molecular Target in Lung Cancer?
    J Natl Cancer Inst. 2017;109:1-3.
    PubMed     Text format    


  10. WELLER M, Roth P, Sahm F, Burghardt I, et al
    Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363.
    J Natl Cancer Inst. 2017;109:1-4.
    PubMed     Text format     Abstract available


  11. KIM SJ, Hyeong Lee T, Hee Nam S, Kim JH, et al
    Association of Uba6-Specific-E2 (USE1) With Lung Tumorigenesis.
    J Natl Cancer Inst. 2017;109:1-11.
    PubMed     Text format     Abstract available


  12. CELIKTAS M, Tanaka I, Tripathi SC, Fahrmann JF, et al
    Role of CPS1 in Cell Growth, Metabolism, and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.
    J Natl Cancer Inst. 2017;109:1-9.
    PubMed     Text format     Abstract available


    January 2017
  13. BROWER V
    Researchers Identify High-Risk Subtype of Stage I Lung Cancer.
    J Natl Cancer Inst. 2017;109:3-4.
    PubMed     Text format    


  14. PELOSOF L, Ahn C, Gao A, Horn L, et al
    Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  15. SHUKLA S, Evans JR, Malik R, Feng FY, et al
    Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


    December 2016
  16. ZUBER V, Marconett CN, Shi J, Hua X, et al
    Pleiotropic Analysis of Lung Cancer and Blood Triglycerides.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available


    October 2016
  17. POLLEY E, Kunkel M, Evans D, Silvers T, et al
    Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available


  18. GAZDAR AF, Minna JD
    Developing New, Rational Therapies for Recalcitrant Small Cell Lung Cancer.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


    July 2016
  19. HO GY, Zheng SL, Cushman M, Perez-Soler R, et al
    Associations of Insulin and IGFBP-3 with Lung Cancer Susceptibility in Current Smokers.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available


  20. ROCHMAN S
    High Glycemic Index Associated With Increased Lung Cancer Risk.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


  21. HEALY MA, Yin H, Reddy RM, Wong SL, et al
    Use of Positron Emission Tomography to Detect Recurrence and Associations With Survival in Patients With Lung and Esophageal Cancers.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available


    June 2016
  22. FILLON M
    Continuing To Smoke After Breast Cancer Diagnosis Lowers Survival Rate.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


    April 2016
  23. WESTBROOK JA, Cairns DA, Peng J, Speirs V, et al
    CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available


    March 2016
  24. SCHILD SE, Ashman JB, Keole SR, Daniels TB, et al
    RE: Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


  25. KOSHY M, Malik R, Mahmood U, Husain Z, et al
    Response.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


  26. GOBBO J, Marcion G, Cordonnier M, Dias AM, et al
    Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format     Abstract available


  27. DELUDE C
    Naming and Staging Lung Cancers.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


    February 2016
  28. TENG CJ, Hu YW, Chen SC, Yeh CM, et al
    Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format     Abstract available


  29. ZINDLER JD, Thomas CR Jr, Hahn SM, Hoffmann AL, et al
    Increasing the Therapeutic Ratio of Stereotactic Ablative Radiotherapy by Individualized Isotoxic Dose Prescription.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format     Abstract available


    January 2016
  30. JENKS S
    Is Lung Cancer Incidence Increasing in Never-Smokers?
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format    


  31. SCHMIDT C
    Metastatic Cells Colonize Implantable Scaffold in Mice.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format    


  32. CORTEZ MA, Ivan C, Valdecanas D, Wang X, et al
    PDL1 Regulation by p53 via miR-34.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format     Abstract available


  33. WONG V, Pavlick D, Brennan T, Yelensky R, et al
    Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format    


  34. ALFANO CM, Bluethmann SM, Tesauro G, Perna F, et al
    NCI Funding Trends and Priorities in Physical Activity and Energy Balance Research Among Cancer Survivors.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format     Abstract available


    December 2015
  35. ROCHMAN S
    Genetic Test Finds Radiation Sensitivity Differs Between Primary Tumor and Metastatic Sites.
    J Natl Cancer Inst. 2015;107:djv397.
    PubMed     Text format    


  36. SAMPSON JN, Wheeler WA, Yeager M, Panagiotou O, et al
    Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types.
    J Natl Cancer Inst. 2015;107:djv279.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: